A while ago, Nostrapharmus predicted that for pharmacos, the ability to attract and build quality relationships with winning partners would increasingly be the key to competitive success. Here, Nostrapharmus looks at a different kind of collaboration: that between companies in the non-competitive space...and discovers that, not only will it make life easier for everyone, it will also benefit both competitiveness and investability.
Nostrapharmus says, ‘Collaboration in the range of non-competitive activities including aspects of manufacturing, development and quality operations will be routine within ten years – and the turning point will come much sooner, as companies and regulators realise that by coming into the arena, they have everything to gain and nothing but pride to lose!’
Non-competitive good?
The level of intimacy of exchange between successful companies will soon be way beyond anything dreamed of or, in many cases, desired by today’s participants. But what is this ‘non-competitive’ space? Are we not talking about something perilously close to collusion? This is the picture I see:
In the competitive space are skills such as portfolio management, investment attraction and forging winning partnerships; business activities including research & development and sales & marketing.
The overlap area is home to activity that I call 'few-to-few' collaboration. Even companies that are in direct competition sometimes see benefits in working together on, for example, the co-development and co-marketing of products.
Finally, in the non-competitive space, are activities in which collaboration poses no threat to corporate interest and in which it will become clear, there is benefit to be derived from sharing and other collaborative activity.
To read the article in full, please click on the pdf link below:
Collaborate for competitive success.pdf
To read the magazine, please click on the link below, the article can be found on page 56:http://viewer.zmags.com/showmag.php?mid=fftpd#/page56/
About Pharma Magazine
Aimed at the international pharmaceutical and bio-pharmaceutical community, Pharma magazine covers every aspect of manufacturing from R&D to finished product. With a worldwide circulation of more than 40,000 individuals, it is the first truly global magazine for the pharma industry, bringing together the disciplines of discovery and development, the drug manufacturing process and the resultant business and management issues. For further information visit the Pharma website at www.pharma-mag.com